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Abstract One-third of all individuals with epilepsy are
resistant to antiepileptic drug (AED) treatment. Antiepi-
leptic treatment response has been suggested to be modu-
lated by genetic polymorphisms of drug efflux transporters.
Several polymorphic variants within the multidrug resis-
tance 1 (MDR1) gene, which encodes the major trans-
membrane efflux transporter P-glycoprotein, have been
proposed to be associated with AED resistance in epilepsy
patients. The aim of this study was to evaluate the effect of
C3435T and G2677T/A polymorphisms of MDR1 on AED
resistance in Turkish children with epilepsy. MDR1
C3435T and G2677T/A were genotyped in 152 patients
with epilepsy, classified as drug-resistant in 69 and drug-
responsive in 83. Genotypes of the C3435T and G2677T/A
polymorphisms were determined by polymerase chain
reaction followed by restriction fragment length polymor-
phism. Genotype and allele frequencies of C3435T and
G2677T/A polymorphisms of the MDR1 gene did not differ
between drug-resistant and drug-responsive epilepsy
patients. Our results suggest that MDR1 C3435T and
G2677T/A polymorphisms are not associated with AED
resistance in Turkish epileptic patients. To clarify the exact
clinical implication of the MDR1 polymorphisms on the
multidrug resistance in epilepsy, further investigations in
various ethnic populations would be necessary.
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Introduction
Epilepsy is one of the most prevalent serious chronic
neurological disorders, effecting approximately 1–2 % of
the population [1]. About 30 % of patients with epilepsy do
not respond to any of two to three first line antiepileptic
drugs (AEDs) despite considerable advances in the therapy
of epilepsy and these patients will develop refractory epi-
lepsy [2]. Although efforts to predict pharmacoresistance
have revealed several risk factors (an early onset of epi-
lepsy, symptomatic or cryptogenic epilepsy, and general-
ized seizure) [3, 4], the mechanisms underlying the
resistance to AEDs in the epilepsy treatment are still not
well-understood.
Some potential mechanisms have been suggested
regarding the transporters of the AEDs. There is accumu-
lating evidence to suggest that an increase of functional
expression of multidrug transporters produces pharmacoki-
netic changes that modify the access of AEDs to central
nervous system targets [5]. Genetic polymorphisms in these
transporters could account for their increased expression
and/or functional activity. These genetic variations could be
linked to changes on pharmacokinetic or pharmacodynamic
of AEDs and effective responsiveness to AEDs [6].
The ATP-binding cassette (ABC) transporters, and
especially ABCB1, are the focus of an international effort
to establish their role in mediating drug resistance in a
variety of human diseases including epilepsy [7]. Human
multidrug resistant transporter gene (MDR1, also known as
ABCB1), which is a member of the ABC superfamily,
encodes a 170-kDa P-glycoprotein (P-gp) [8]. The P-gp is
M. Seven  G. Yesil  A. Yuksel
Department of Medical Genetics, Cerrahpasa Medical Faculty,
Istanbul University, Istanbul, Turkey
B. Batar  S. Unal  M. Guven (&)
Department of Medical Biology, Cerrahpasa Medical Faculty,
Istanbul University, Istanbul, Turkey
e-mail: mgguven@istanbul.edu.tr; mguven66@gmail.com
123
Mol Biol Rep (2014) 41:331–336
DOI 10.1007/s11033-013-2866-y
of particular interest, and was first identified in cancer cells,
as a protein responsible for resistance to a wide variety of
AEDs [9]. The transmembrane P-gp that functions as a
multispesific drug-efflux transporter is considered to be
associated with drug absortion and elimination. It is
hypothesized that overexpression of an efflux transporter
such as P-gp around an epiloptegenic focus, via reducing
AED accumulation, may prevent AEDs from entering sites
of action [10].
The expression, efflux, substrate spesificity, and mRNA
stability of P-gp are influenced by various single nucleotide
polymorphisms (SNPs) in the encoding gene, MDR1 [11].
Evidence is present for supporting the important role
played by more gene polymorphisms on the function of
P-gp via effecting its activity [12, 13]. The MDR1 gene is
highly polymorphic with more than 50 variants residing in
the coding region and, which can possibly cause altered
function [14].
A great number of studies were focused on two most
common SNPs, C3435T (Exon 26, rs1045642) and
G2677T/A (Exon 21, rs2032582) SNPs, to explore the
associations with disease development and drug response
in different populations [10]. The synonymous C3435T
polymorphism was the first SNP, which has been shown to
correlate with the expression levels and function of P-gp
[15], although conflicting reports have subsequently
appeared showing no correlation with the expression levels
and function of P-gp [12]. The C3435T polymorphism is in
linkage disequilibrium with nonsynonymous G2677T/A
polymorphism (Ala893Ser/Thr), which may also contribute
to the observed functional effect of variation at the C3435T
polymorphism or at associated haplotypes [16]. Further-
more, the G2677T/A SNP has been shown to be associated
with drug resistant epilepsy [17, 18]. Thus, the MDR1 has
been regarded as an interesting candidate gene potentially
influencing the response to AED treatment.
Based on the hypothesis that MDR1 genetic polymor-
phisms can modulate drug response phenotype in epilepsy,
the present study was carried out to evaluate the association
of two SNPs [3435C [ T (rs1045642) and 2677G [ T/A
(rs2032582)] of the MDR1 gene in drug-responsive and
drug-resistance patients in a Turkish population.
Materials and methods
Study population
A total of 152 Turkish children with epilepsy treated with
AEDs were included in this study. The patients were
diagnosed and classified according to the guidelines of the
International League against Epilepsy. Patients, who had
an established clinical diagnosis of epilepsy (defined by the
occurrence of two or more unprovoked seizures) confirmed
by an electroencephalogram examination by an expert were
included in the study. Exclusion criteria consisted of severe
adverse drug reactions, poor compliance with AEDs, his-
tory of pseudo-seizures, alcohol or drug abuse, or any other
malignant diseases such as brain tumor, secondary metas-
tasis, hepatic failure, or renal failure.
Patients were included if they had either drug-resistant or
drug-responsive epilepsy according to the following defini-
tions and criteria. The main criterion for drug resistance was
the occurrence of at least four seizures over a period of 1 year
with three AEDs, such as carbamazepine ? valproate ?
levetiracetam, or carbamazepine ? valproate ? diphenyl
hydantoin, according to the epileptic seizure type at maxi-
mum tolerated doses. Of the 152 patients, 69 were classified
as drug resistant (40 males, 29 females, mean age:
9.2 ± 3.6 years) and 83 were drug responsive (51 males, 32
females, mean age: 9.3 ± 3.8 years.
The protocol for this study was approved by the
Regional Ethics Committee and was carried out in accor-
dance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments
involving humans. An informed consent was signed by
each participant or responsible adult.
Blood samples and DNA isolation
Venous blood samples (3 ml) were collected in EDTA
vacutainer tubes for DNA extraction. Immediately after
collection, whole blood was stored in aliquots at -20 C
until use. Genomic DNA was extracted from leukocytes
using Roche DNA purification kit (Roche Diagnostics
GmbH, Mannheim, Germany) according to the manufac-
turer’s instructions.
Genotyping
Genotyping of MDR1 C3435T (exon 26) and G2677T/A
(exon 21) were determined by using the polymerase chain
reaction–restriction fragment length polymorphism (PCR–
RFLP) assay. PCR amplifications of exon 26 and 21 of the
MDR1 gene were performed with primers described by
Tanabe et al. and Cascorbi et al., respectively [19, 20].
PCR amplifications were carried out in a total volume of
25 ll containing: 100 ng of genomic DNA, 1U of Taq
Polymerase (MBI Fermentas), 1 lM of each primer [for
C3435T, F:50-TTG ATG GCA AAG AAA TAA AGC-30
and R:50-CTT ACA TTA GGC AGT GAC TCG-30; for
G2677T/A, F:50-TTT GCA GGC TAT AGG TTC CAG-30,
R(A):50GTT TGA CTC ACC TTC CCA G-30 and R(T):50-
TTT AGT TTG ACT CAC CTT CCC G-30], 1X PCR
buffer, 1 mM MgCl2, and 0.04 mM dNTPs. The amplifi-
cation reactions were performed in a thermocycler 9700
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(Applied Biosystems, California, USA) under the follow-
ing conditions: For MDR1 C3435T polymorphism, initial
denaturation at 94 C for 4 min, followed by 35 cycles
each of 94 C for 30 s, 56 C for 30 s, 72 C for 30 s; and
a final extension at 72 C for 5 min; for MDR1 G2677T/A
polymorphism, initial denaturation at 94 C for 3 min,
followed by 40 cycles each of 94 C for 20 s, 55 C for
20 s, 72 C for 30 s; and a final extension at 72 C for
5 min. The PCR products were digested by restriction
endonucleases of MboI at 37 C (for C3435T), BanI at
37 C (for G2677T) and BsrI at 65 C (for G2677A) for
3 h and analyzed with 3 % agarose gel electrophoresis.
Statistical analysis
Mean and standard deviations (SDs) are presented in case
of continuous variables. Differences between the means of
the two continuous variables were evaluated by the Stu-
dent’s t test. Chi square (v2) or Fischer’s exact test (two-
sided) was used to compare the association between the
genotypes and alleles in relation to the cases, and test for
deviation of genotype distribution from Hardy–Weinberg
equilibrium. P values of \0.05 were considered statisti-
cally significant. The odds ratio (OR) and their 95 %
confidence intervials (CIs) were calculated to estimate the
strength of the association. Statistical analysis was per-
formed using a statistical software package, SPSS 16.0
(SPSS Inc, USA). Haplotype frequency analysis and link-
age disequilibrium for the two MDR1 polymorphisms were
performed by using the Haploview 4.2 program.
Results
Basic demographic and clinical charecteristics of epilepsy
patients with drug-resistant and drug-responsive are pre-
sented Table 1. The groups were not significantly different
with respect to the age and gender (all values of P [ 0.05).
No significant deviations from Hardy–Weinberg equi-
librium were observed in epilepsy patients (P = 0.68 for
MDR1 C3435T and P = 1.00 for MDR1 G2677T/A).
Table 2 shows the genotype and allele frequencies of the
polymorphisms in MDR1 gene for both drug-resistant and
drug-responsive epilepsy patients. The distribution of
MDR1 C3435T and G2677T/A genotypes within drug-
resistant (P = 0.76 and P = 1.00, respectively) and drug-
responsive (P = 0.88 and P = 0.98, respectively) groups
were not significantly different from that under Hary–
Weinberg equilibrium. No statistically significant differ-
ences were detected for the genotype and allele frequencies
of the polymorphisms in the MDR1 gene between the drug-
resistant and drug-responsive groups.
Table 3 lists the haplotypes of MDR1 polymorphisms in
the drug-resistant and drug-responsive epilepsy patients.
Haplotype frequencies of these polymorphisms in the
MDR1 gene did not differ significantly between drug-
resistant and drug-responsive epilepsy patients. The link-
age disequilibrium test of two SNPs in MDR1 (Rs1045642
and rs2032582) were in strong linkage disequilibrium
(D0 = 0.991).
Discussion
Drug-resistant epilepsy patients tend to be resistant to a
broad range of AEDs with a varied mode of action [5, 7].
The functional characteristics of non-specific drug trans-
porter proteins could explain broader resistance across
types of epilepsy and to a range of AEDs [21]. Among
these transporter proteins, P-gp is considered as one of the
most potent contributer to the phenomenon of clinical drug
resistance to AEDs.
Various genetic polymorphisms in the MDR1 gene
could be linked with altered in vivo transport activity of
P-gp which may play a facilitatory role in drug-resistant
epilepsy [6]. These genetic polymorphisms among epilepsy
patients are likely to contribute to different responses in
patients, who have similar epilepsy syndromes and are
taking similar, or even the same, doses of medication.
So in the present study, we investigated two SNPs in
MDR1 gene in drug-resistant and drug-responsive epilepsy
patients. Results of the present study demonstrated that
genotype and allele frequencies of C3435T and G2677T/A
polymorphisms of the MDR1 gene did not differ between
drug-responsive and drug resistant epilepsy patients.
Table 1 Demographic and clinical characteristics of epilepsy
patients
Parameters Drug-resistant n (%) Drug-responsive n (%)
Gender
Male 40 (58) 51 (61)
Female 29 (42) 32 (39)
Age (years)
Mean ± SD 9.2 ± 3.6 9.3 ± 3.8
Range 1–15 2–14
Seizure type
Partial 24 (35) 24 (29)
Generalized 45 (65) 59 (71)
Etiology
Idiopathic 31 (45) 40 (48)
Symptomatic 29 (42) 27 (33)
Cryptogenic 9 (13) 16 (19)
SD standard deviation
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Furthermore, the results of this study also showed no
haplotype association of these MDR1 polymorphisms with
drug-resistant epilepsy.
The results from various studies focusing on the role of
MDR1 C3435T and G2677T/A polymorphisms in AED
responsiveness are conflicting. Consistent with the present
study, several studies have found no significant associations
between drug-resistance epilepsy and the MDR1 C3435T
and G2677T/A polymorphisms [22, 23]. Two studies from
Turkey also reported that there were no associations
between the polymorphisms of the MDR1 gene and drug-
resistant epilepsy [24, 25]. Similarly, Kim et al. [26]
observed no association between the polymorphisms of
G2677T/A and 3435C [T and drug resistance in Korean
patients. However, contrary to the above studies’ results,
Hung et al. [17] found that 3435C[T and 2677G[T in the
MDR1 gene contributed to drug-resistant epilepsy. Siddiqui
et al. [27] demonstrated that the frequency of the 3435CC
genotype among drug-resistant patients (27.5 %) was
significantly higher than in drug-responsive patients or
nonepileptic controls (15.7 or 18.5 %, respectively) among
Caucasian subjects. In contrast to these results, Kwan et al.
[28] reported that patients with drug-resistant epilepsy had a
higher frequency of the 3435TT genotype (16.7 %) in
comparison to drug-responsive epileptics or nonepileptic
controls (10.6 or 7.4 %, respectively). Furthermore, Seo
et al. also demonstrated that drug-resistant epilepsy patients
were significantly more likely to have the T allele and the
TT genotype at C3435T when compared to drug-responsive
patients (50 vs 27; 36.9 vs 16.7 %, respectively). In addi-
tion, Seo et al. [29] found that patients with drug-resistant
epilepsy had higher frequencies of the TT genotypes at
G2677T/A in comparison to the drug-responsive patients
(26.2, 23.8 %, respectively).
The differences observed in these reports may be due to
the ethnic differences in genotype/allele frequencies.
Genetic polymorphisms often vary between ethnic groups.
Ethnic differences in genotype frequency for the investi-
gated polymorphisms might effect the results in genetic
studies. Distribution of MDR1 C3435T polymorphism also
displays an ethnic difference. For example, MDR1 3435CC
was less common than 3435TT in Caucasian patients
(16–19 vs 27–33 % in drug-responsive patients) [22, 27],
while the opposite of this was observed in Han Chinese
cohort (38 vs 7 % in drug responsive patients) [28], similar
to other Asian populations [30]. Furthermore, contradictory
data reported in these epidemiologic studies may be due to
other several factors such as number of patients, combi-
nations of susceptibility variants, the isolated nature of
the study populations, heterogeneity of epilepsy and gene-
environment interactions.
Table 2 Genotype and allele
distribution of the MDR1
C3435T and G2677T/A
polymorphisms in drug resistant
and drug-responsive patients
with epilepsy








OR (95 % CI) P-value
C3435T
CC 17 (25) 22 (26) Ref.
CT 30 (43) 38 (46) 1.02 (0.46–2.26) 0.96
TT 22 (32) 23 (28) 1.24 (0.52–2.93) 0.63
C allele frequency 0.46 0.49 Ref.
T allele frequency 0.54 0.51 1.13 (0.65–1.97) 0.67
G26677T/A
GG 17 (25) 20 (24) Ref.
GT 32 (46) 36 (43) 1.05 (0.47–2.33) 0.91
TT 17 (25) 24 (29) 0.83 (0.34–2.04) 0.69
GA 1 (1) 2 (3) 0.59 (0.05–7.07) 1.00
TA 2 (3) 1 (1) 2.35 (0.20–28.27) 0.60
AA 0 (0) 0 (0) – –
G allele frequency 0.49 0.47 Ref.
T allele frequency 0.49 0.52 0.90 (0.52–1.58) 0.72
A allele frequency 0.02 0.01 1.92 (0.17–21.87) 1.00
Table 3 MDR1 C3435T and G2677T/A haplotype frequencies in
drug-resistant and drug-responsive patients with epilepsy
Haplotype Frequency P-value
Drug-resistant Drug-responsive
TT 0.535 0.526 0.988
CG 0.409 0.404 0.972
TG 0.044 0.035 0.487
CT 0.012 0.035 0.235
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The authors assessed the association of MDR1 hap-
lotypes derived from C3435T, G2677T/A, and C1236T
loci in response to AEDs in different epilepsy popula-
tions [31]. In consistency with our results, Alpman et al.
[25] found that the haplotypes of C3435T and G2677T/A
were not associated with drug resistant epilepsy in
Turkish epileptics. Furthermore, Meng et al. [32] failed
to detect any associations between drug-resistance and
haplotypes of C3435T, G2677T/A, and C1236T poly-
morphisms. However, Siddiqui et al. [27] reported
that the C–G–C haplotype of C3435T, G2677T/A, and
C1236T was associated with the AED-resistance. Zim-
prich et al. [18] also identified that C–G–C haplotype
significantly increased the risk for pharmacoresistance.
Contrary to this, Seo et al. [29] found that patients with
drug-resistant epilepsy had higher frequencies of the
T–T–T haplotype at C3435T, G2677T/A, and C1236T
than patients with drug-responsive epilepsy (42.1,
30.4 %, respectively).
In conclusion, our results indicate that MDR1 C3435T
and G2677T/A polymorphisms are not associated with
drug-resistant epilepsy in the study population. The limi-
tation of the current study is the small sample size. To
clarify the exact clinical implication of the MDR1 poly-
morphisms on the multidrug resistance in epilepsy, further
investigations in various ethnic populations would be
necessary.
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